Articles
Ideas shaping biotechnology growth—commercial leadership, launch strategy, and rare disease insights from PharmaKonsult.
Choosing the Right Commercial Direction in Biotechnology
Most biotech companies never intend to become fully integrated pharma organizations. Three strategic directions shape how value is created—and commercial planning matters in all of them.
Read articleThe Real Reason So Many Rare Disease Therapies Never Reach Patients
Clinical trial failure is the common explanation—but the deeper issue often begins earlier, when scientific models and disease-market understanding are incomplete.
Read articleCommercial Culture Is Often the Difference Between Product Launch Success and Struggle
Superior clinical data matters—but commercial culture, leadership alignment, and removing barriers to patient access often decide whether a launch succeeds or stalls.
Read articleEarlier Diagnosis of Cushing's Syndrome: The Greatest Opportunity May Not Be a New Therapy
Despite advances in treatment, patients with Cushing's syndrome are still diagnosed far too late. The greater opportunity may be earlier clinical recognition—not another therapy.
Read articleSelecting the Right Commercial Leader for Biotechnology Success
A structured framework for evaluating commercial leadership candidates—so biotechnology companies, boards, and investors can hire with clearer judgment and lower risk.
Read article